+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

The absence of a pharmacokinetic interaction between aspirin and the angiotensin-converting enzyme inhibitor benazepril in healthy volunteers



The absence of a pharmacokinetic interaction between aspirin and the angiotensin-converting enzyme inhibitor benazepril in healthy volunteers



Biopharmaceutics and Drug Disposition 15(6): 451-461



Potential effects of the coadministration of single doses of aspirin (325 mg) and of benazepril hydrochloride (20 mg) on the pharmacokinetics and the metabolism of these two drugs were evaluated in 12 healthy subjects. Plasma concentration profiles of benazepril, its active metabolite benazeprilat, and total salicylic acid were determined together with urinary excretion of benazeprilat, salicylic acid, salicyluric acid, and salicylate glucuronides. Almost superimposable plasma profiles of benazepril, benazeprilat, and total salicylic acid were achieved with the drugs given alone and concomitantly. The coadministration of benazepril hydrochloride and aspirin did not modify the pharmacokinetics or the metabolism of the two drugs.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 047575045

Download citation: RISBibTeXText

PMID: 7993983

DOI: 10.1002/bdd.2510150603


Related references

The absence of a pharmacokinetic interaction between aspirin and the angiotensin-converting enzyme inhibitor benazepril in the healthy volunteers. Biopharmaceutics & Drug Disposition 15(6): 451-461, 1994

Pharmacokinetic and -dynamic interaction trial with digoxin and the angiotensin-converting enzyme inhibitor imidapril in healthy volunteers. European Heart Journal 17(ABSTR Suppl. ): 60, 1996

Pharmacokinetics of the angiotensin converting enzyme inhibitor benazepril.HCl (CGS 14 824 A) in healthy volunteers after single and repeated administration. Biopharmaceutics and Drug Disposition 10(4): 365-376, 1989

Pharmacokinetics of the angiotensin converting enzyme inhibitor benazepril hydrochloride cgs 14824a in healthy volunteers after single and repeated administration. Biopharmaceutics & Drug Disposition 10(4): 365-376, 1989

Radioimmunoassay for ceronapril, a new angiotensin-converting enzyme inhibitor, and its application to a pharmacokinetic study in healthy male volunteers. Therapeutic Drug Monitoring 14(3): 209-219, 1992

Pharmacokinetic properties of a new angiotensin converting enzyme inhibitor altiopril calcium in normal healthy volunteers and patients with renal dysfunction. Current Therapeutic Research 47(2): 297-305, 1990

Renal effects of benazepril a new angiotensin i converting enzyme inhibitor in rats and dogs interaction with diuretics. Naunyn-Schmiedeberg's Archives of Pharmacology 339(Suppl.): R43, 1989

Multi-spectroscopic approaches and molecular simulation research of the intermolecular interaction between the angiotensin-converting enzyme inhibitor (ACE inhibitor) benazepril and bovine serum albumin (BSA). Spectrochimica Acta. Part A Molecular and Biomolecular Spectroscopy 212: 15-24, 2019

Effects of benazepril, an angiotensin-converting enzyme inhibitor, combined with CGS 35066, a selective endothelin-converting enzyme inhibitor, on arterial blood pressure in normotensive and spontaneously hypertensive rats. Clinical Science 103(Suppl. 48): 363s-366s, 2002

Effects of MDL 100,240, a dual inhibitor of angiotensin-converting enzyme and neutral endopeptidase on the vasopressor response to exogenous angiotensin I and angiotensin II challenges in healthy volunteers. Journal of Cardiovascular Pharmacology 31(3): 408-417, 1998

Benazepril, an angiotensin converting enzyme inhibitor: Drug interaction with salbutamol and bronchial response to histamine in normal subjects. British Journal of Clinical Pharmacology 44(6): 573-575, 1997

Plasma concentrations of an angiotensin-converting enzyme inhibitor, benazepril, and its active metabolite, benazeprilat, after repeated administrations of benazepril in dogs with experimental kidney impairment. Journal of Veterinary Medical Science 62(2): 179-185, 2000

Pharmacokinetic/Pharmacodynamic Modeling of Renin-Angiotensin Aldosterone Biomarkers Following Angiotensin-Converting Enzyme (ACE) Inhibition Therapy with Benazepril in Dogs. Pharmaceutical Research 32(6): 1931-1946, 2015

Pharmacological study of alacepril an angiotensin i converting enzyme inhibitor in healthy volunteers. Current Therapeutic Research 42(2): 324-334, 1987

Central effects of the angiotensin converting enzyme inhibitor captopril in healthy volunteers. British Journal of Clinical Pharmacology 28(2): 228P-229P, 1989